Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

NCT03220035 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

4

Enrollment

NIH

Sponsor class

Conditions

Advanced Malignant Solid Neoplasm
Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Ependymoma
Ewing Sarcoma
Hepatoblastoma
Langerhans Cell Histiocytosis
Malignant Germ Cell Tumor
Malignant Glioma
Osteosarcoma
Peripheral Primitive Neuroectodermal Tumor
Recurrent Childhood Central Nervous System Neoplasm
Recurrent Childhood Non-Hodgkin Lymphoma
Recurrent Malignant Solid Neoplasm
Recurrent Neuroblastoma
Refractory Malignant Solid Neoplasm
Refractory Neuroblastoma
Refractory Non-Hodgkin Lymphoma
Refractory Primary Central Nervous System Neoplasm
Rhabdoid Tumor
Rhabdomyosarcoma
Soft Tissue Sarcoma
Wilms Tumor

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Vemurafenib

Sponsor

National Cancer Institute (NCI)